PSEN1 and leukemia: MRK-560 treatment decreases leukemia burden and increased OS with no associated gut toxicity in T-ALL patient-derived xenografts in vivo, suggesting that, similar to SERCA inhibition, disruption of PSEN-1 may preferentially affect mutated proteins [179].